Formulation of Budesonide-Loaded Polymeric Nanoparticles into Hydrogels for Local Therapy of Atopic Dermatitis

Abstract

Budesonide is a mineral corticoid applied in the local therapy of pediatric atopic dermatitis. Unfortunately, its dermal administration is hindered by the concomitant adverse effects and its physicochemical properties. The characteristic pH change in the atopic lesions can be utilized for the preparation of a pH-sensitive nanocarrier. In this view, the formulation of Eudragit L 100 nanoparticles as a budesonide delivery platform could provide more efficient release to the desired site, improve its penetration, and subsequently lower the undesired effects. In this study, budesonide-loaded Eudragit L100 nanoparticles were prepared via the nanoprecipitation method (mean diameter 57 nm, −31.2 mV, and approx. 90% encapsulation efficiency). Their safety was proven by cytotoxicity assays on the HaCaT keratinocyte cell line. Further, the drug-loaded nanoparticles were incorporated into two types of hydrogels based on methylcellulose or Pluronic F127. The formulated hydrogels were characterized with respect to their pH, occlusion, rheology, penetration, spreadability, and drug release. In conclusion, the developed hydrogels containing budesonide-loaded nanoparticles showed promising potential for the pediatric treatment of atopic dermatitis.

Development of an Emulgel for the Effective Treatment of Atopic Dermatitis: Biocompatibility and Clinical Investigation

“…Topical treatments are sufficient for mild to moderate AD management [ 14 ]. Current therapies are focused on reducing inflammation, restoring the skin barrier, and antibacterial therapy [ 14 ].…”

“…Current therapies are focused on reducing inflammation, restoring the skin barrier, and antibacterial therapy [ 14 ]. Local corticosteroids are used as a first-line treatment to treat moderate to severe AD, but long-term use will lead to telangiectasia, skin thinning, epidermal atrophy, and other adverse effects [ 14 , 15 ]. Daily moisturization is one of the cornerstones of AD treatment [ 16 ].…”